Seliciclib
- Generic Name
- Seliciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H26N6O
- CAS Number
- 186692-46-6
- Unique Ingredient Identifier
- 0ES1C2KQ94
- Background
R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.
- Indication
Investigated for use/treatment in breast cancer, lung cancer, lymphoma (unspecified), multiple myeloma, leukemia (lymphoid), and cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT03774446
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Treatment of Cushing's Disease With R-roscovitine
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Shlomo Melmed, MD
- Target Recruit Count
- 4
- Registration Number
- NCT02160730
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01333423
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT00372073
- Locations
- 🇺🇸
Pasco Hernando Oncology, New Port Richey, Florida, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Pacific Coast Hematology Oncology Group, Fountain Valley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.